首页/数据集/Multivariate analysis of risk factors for post-extraction bleeding events (rivaroxaban).

Multivariate analysis of risk factors for post-extraction bleeding events (rivaroxaban).

NIAID Data Ecosystem2026-03-13 收录

数据链接：

https://figshare.com/articles/dataset/Multivariate_analysis_of_risk_factors_for_post-extraction_bleeding_events_rivaroxaban_/19541231 数据链接链接失效反馈

官方服务：

资源简介：

Multivariate analysis of risk factors for post-extraction bleeding events (rivaroxaban).

应用场景：

创建时间：

2022-04-07

相关数据集

FRAIL-AF

老年心房颤动抗凝治疗

抗凝药物安全性

The FRAIL-AF trial was a pragmatic, multicenter, open-label, randomized controlled superiority trial on the safety of switching from a vitamin K antagonist (VKA) to a non- vitamin K oral anticoagulant

DataCite Commons2025-07-03 更新90

Dataset from RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

抗凝药物安全性

临床知识转化

The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes

NIAID Data Ecosystem30

Warfarin Anticoagulation Exacerbates the Risk of Hemorrhagic Transformation after rt-PA Treatment in Experimental Stroke: Therapeutic Potential of PCC

缺血性中风治疗

抗凝药物安全性

BackgroundOral anticoagulant therapy (OAT) with warfarin is the standard of stroke prevention in patients with atrial fibrillation. Approximately 30% of patients with cardioembolic strokes are on OAT

Figshare2016-01-18 更新20

Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants

抗凝药物安全性

肾功能临床结局

We aimed to compare renal function changes in patients with atrial fibrillation (AF) prescribed different oral anticoagulants (OACs). We performed a retrospective analysis of Australian national prim

NIAID Data Ecosystem30

Unadjusted annual cumulative incidence of bleeding among non-valvular atrial fibrillation (nvaf) patients who initiated apixaban, dabigatran, or rivaroxaban.

抗凝药物安全性

心房颤动治疗

Unadjusted annual cumulative incidence of bleeding among non-valvular atrial fibrillation (nvaf) patients who initiated apixaban, dabigatran, or rivaroxaban.

NIAID Data Ecosystem20